论文部分内容阅读
目的:探讨抗纤胶囊对四氯化碳(CCL4)诱导的实验性大鼠肝纤维化的治疗作用。方法:40只雄性SD大鼠随机分为正常对照组、模型组、秋水仙碱组、抗纤胶囊高、低剂量组。除正常对照组外,各组大鼠均采用CCl4和高脂饲料复合诱导制备大鼠肝纤维化模型,同时治疗组分别每天ig抗纤胶囊(0.637 5,0.425 g.kg-1)和秋水仙碱(1.562 5×10-4g.kg-1),干预6周,对照组和模型组动物每天ig生理盐水。采用全自动生化分析仪检测血清丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)活性,放射免疫法检测血清透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)的含量,光镜下观察肝组织病理改变。结果:模型组大鼠肝组织内肝细胞广泛变性及坏死,大量炎性细胞浸润,类假小叶形成,大量胶原纤维形成;抗纤胶囊治疗组的肝脏病理变化程度较模型组明显减轻且无类假小叶形成。抗纤胶囊(0.637 5,0.425 g.kg-1)组的ALT和AST活性为(70.88±20.66),(86.25±22.05)U.L-1,(131.50±31.52),(151.25±38.66)U.L-1;抗纤胶囊(0.637 5,0.425 g.kg-1)组的HA,LN,PCⅢ的含量为(340.93±64.75),(363.88±80.44)ng.L-1,(261.59±56.93),(311.84±61.60)ng.L-1,(61.67±14.51),(76.47±19.68)μg.L-1,与模型组比较,抗纤胶囊治疗组大鼠的血清ALT,AST,HA,LN,PCⅢ水平显著降低(P<0.01)。结论:抗纤胶囊对CCL4诱导的大鼠具有较好的抗肝纤维化作用。
Objective: To investigate the therapeutic effect of Kangxian Capsule on carbon tetrachloride (CCL4) -induced experimental rat hepatic fibrosis. Methods: Forty male SD rats were randomly divided into normal control group, model group, colchicine group and Kangxian Capsule high and low dose groups. Except for the normal control group, rats in each group were induced with CCl4 and high-fat diet to induce liver fibrosis in rats. At the same time, the treatment groups were given ig Kangxian Capsule (0.637 5,0.425 g.kg-1) (1.562 5 × 10-4g.kg-1) for 6 weeks. The animals in control group and model group were given ig saline daily. Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured by automatic biochemical analyzer. Serum hyaluronic acid (HA), laminin (LN) Type procollagen (PC Ⅲ) content, observed under light microscope pathological changes of liver tissue. Results: The liver cells in the model group were extensively degenerated and necrotic, with a large number of inflammatory cells infiltrating, pseudolobule formation and a large number of collagen fibers forming. The liver pathological changes in the anti-fibrinolytic group were significantly reduced compared with the model group False lobule formation. The ALT and AST activities of Kangfang Capsules group were (70.88 ± 20.66), (86.25 ± 22.05) UL-1, (131.50 ± 31.52), (151.25 ± 38.66) UL-1 (340.93 ± 64.75), (363.88 ± 80.44) ng.L-1, (261.59 ± 56.93) and (311.84) in the anti-fibrosis capsule group (0.637 5 and 0.425 g · kg- ± 61.60) ng.L-1, (61.67 ± 14.51) and (76.47 ± 19.68) μg.L-1, respectively.Compared with the model group, the levels of ALT, AST, HA, LN and PCⅢ Significantly lower (P <0.01). Conclusion: Kangxian Capsule has good anti-hepatic fibrosis effect on CCL4-induced rats.